Diasorin SpA (CHIX:DIAM) Other Long-Term Liabilities: €226 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIAM Diasorin SpA CHIX:DIAM
78 GF Score
Price €70.23
GF Value €93.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Diasorin SpA Other Long-Term Liabilities?

Diasorin SpA CHIX:DIAM 78 Other Long-Term Liabilities is €226 Mil as of Dec. 2025. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €93.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Diasorin SpA's other long-term liabilities for the quarter that ended in Dec. 2025 was €226 Mil.

Diasorin SpA's quarterly other long-term liabilities declined from Jun. 2025 (€217 Mil) to Sep. 2025 (€0 Mil) but then increased from Sep. 2025 (€0 Mil) to Dec. 2025 (€226 Mil).

Diasorin SpA's annual other long-term liabilities declined from Dec. 2023 (€1,321 Mil) to Dec. 2024 (€1,199 Mil) and declined from Dec. 2024 (€1,199 Mil) to Dec. 2025 (€226 Mil).

Diasorin SpA Other Long-Term Liabilities Related Terms

Diasorin SpA Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Other Long-Term Liabilities Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,524.07 1,508.84 1,321.04 1,198.66 226.17

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 216.94 0.00 226.17 0.00
CHIX:DIAM
78GF Score
Diasorin SpA CHIX:DIAM
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €226 Mil mean?
Diasorin SpA (CHIX:DIAM) has a Other Long-Term Liabilities of €226 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Other Long-Term Liabilities too high?
Diasorin SpA's current Other Long-Term Liabilities is €226 Mil. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Other Long-Term Liabilities compare to TMO and DHR?
Diasorin SpA's Other Long-Term Liabilities of €226 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Other Long-Term Liabilities is €226 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €93.99, compared to a current price of €70.23 — trading 25.3% below its estimated fair value. The current Other Long-Term Liabilities is €226 Mil. Diasorin SpA's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current Other Long-Term Liabilities is €226 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €70.23 is trading 25.3% below its estimated GF Value™ of €93.99. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for CHIX:DIAM:

  • Other Long-Term Liabilities: €226 Mil
  • GF Value™: €93.99 vs. price of €70.23 (25.3% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score

Get the complete analysis for CHIX:DIAM

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.23
Price
€93.99
GF Value